Recipient
Northern RNA Inc.Department
National Research Council CanadaAmount
$7.0M
Province
ABType
Contribution
Agreement Number
172-2022-2023-Q4-1003190
Purpose
The COVID-19 pandemic has impacted the global supply of nucleic acid products including mRNA and plasmid DNA and delivery vehicles such as lipid nanoparticles which have been demonstrated to be important tools for outbreak management predominately via a mass vaccination approach. The time to market for these products is hindered by complexities in production, production processes, analytical methods, and complicated supply chain, intellectual property landscape and quality management systems. Northern RNA's intention is to provide agile platform production approaches and enabling systems, infrastructure, and resources to ensure access to nucleic acid products and their formulations for researchers, organizations, and healthcare providers in managing the current pandemic and to heighten domestic and global preparedness for the future.
Northern RNA Inc. × National Research Council Canada
3 grants totalling $7.1M
Industrial Research Assistance Program – Contributions to Firms
1,000 grants totalling $122.3M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Providence Therapeutics Holdings Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |